It’s an exciting time to be in MR. The continuous demand for MR imaging, fueled by the increasing disease burden and population demographics, continues to feed MR procedures growth and expansion across multiple clinical specialties, from neurology and oncology to cardiology, pediatrics and sports medicine. In China we see growing interest in high precision tools for neuro and oncology assessment, such as PET/MR and 7.0T. In Europe, several institutions seek to incorporate more sustainable solutions to their departments to remain energy, helium and operationally efficient. In North America, the clinical pressures of complex imaging examinations, increasing referral backlogs and staffing shortages demand higher productivity and more efficient and patient-friendly workflows.
At GE HealthCare, we are preparing for tomorrow with intelligent, future-forward MR systems and technologies. As Kelly Londy writes, our focus is to solve our customers’ primary needs: fast, accurate MR imaging, increased geographical, demographical and clinical access to care for all patients, and actionable diagnostic insights. We’re excited to share that our latest innovations deliver on the promise of more accurate, accessible and actionable health outcomes.
This year at the 2024 Annual Meeting of the Radiological Society of North America (RSNA), we are excited to announce the US FDA clearance of SIGNA™ MAGNUS‡, an ultra-high performance 3.0T head-only MRI system designed to advance both clinical imaging and neuroscientific discovery. We also unveil the US FDA-pending Sonic DL™ for 3D‡‡, enabling up to 12-times acceleration factors for brain, spine, orthopedic and body imaging, as well as the compatibility of Sonic DL with AIR™ Recon DL for an altogether better diagnostic result at ultra-high speed with ultra-high clarity. Finally, we are happy to showcase our latest 1.5T MRI system, SIGNA™ Champion, a high-throughput, scalable and sustainable platform designed for patients everywhere.
Accuracy, accessibility and adaptability are the words that best describe the latest advancements in MR from GE HealthCare. From the neurological precision of SIGNA MAGNUS to the equitable access the SIGNA™ Continuum™ upgrade program offers across the GE HealthCare MR fleet and to the adaptability and versatility of deep-learning techniques such as Sonic DL and AIR Recon DL, we are committed to innovating MR for everyone by making our solutions available across our portfolio. Our oath to you is that GE HealthCare will continue to enable clinicians to improve access and outcomes for patients everywhere.
‡ SIGNA MAGNUS is 510(k) cleared with the US FDA. Not yet CE Marked. Not available for sale in all regions.
‡‡ 510(k) pending at US FDA. Not yet CE marked. Not available for sale.
- Previous
- More to explore with SIGNA MAGNUS
